A. FURTHER INFORMATION ABOUT OUR GROUP

1. Incorporation of our Company

Our Company was incorporated in the Cayman Islands under Cayman Companies Act as an exempted company with limited liability on 7 August 2024. Our registered office is at the offices of Vistra (Cayman) Limited, P.O. Box 31119, Grand Pavilion, Hibiscus Way, 802 West Bay Road, Grand Cayman, KY1-1205, Cayman Islands. Accordingly, our corporate structure and Articles of Association are subject to the relevant laws of the Cayman Islands. A summary of certain aspects of the Cayman Islands company law and a summary of certain provisions of our Articles of Association are set out in "Appendix IV — Summary of the Constitution of the Company and Cayman Islands Company Law" to this document.

Our registered place of business in Hong Kong is at 46/F, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong. We have registered as a non-Hong Kong Company under Part 16 of the Companies Ordinance on February 27, 2025. Mr. NG Tung Ching Raphael (吳東澄), one of our joint company secretaries, has been appointed as the authorized representative of our Company for the acceptance of the service of process on behalf of our Company in Hong Kong. The address for the service of process is the same as our principal place of business in Hong Kong.

2. Changes in the Share Capital of Our Company

Save as disclosed in "History, Reorganization and Corporate Structure," there has been no other alteration in the share capital of our Company during the two years immediately preceding the date of this document.

3. Changes in the Share Capital of Our Subsidiaries

A summary of the corporate information and the particulars of our subsidiaries are set out in Note 1 to the Accountants' Report as set out in Appendix I to this document.

On May 27, 2024, Suzhou Huge was established in the PRC as a limited liability company with its registered capital being RMB5,000,000.

On May 13, 2024, the registered capital of Qingdao Technology was increased from RMB11 million to RMB11.1 million.

Save as disclosed above and as disclosed in the section headed "History, Reorganization and Corporate Structure" in this document, there has been no alteration in the share capital of any of our subsidiaries during the two years immediately preceding the date of this document.

4. Resolutions of Shareholders of Our Company Passed on [●]

Written resolutions of our Shareholders were passed on [●], pursuant to which, among others:

(a) the Memorandum and Articles of Association was approved and adopted conditional upon [**REDACTED**];

(b) conditional upon all the conditions set out in "Structure of the [**REDACTED**]" being fulfilled:

(i) the Share Subdivision, the [**REDACTED**] and the [**REDACTED**] [was approved];

(ii) the Board (or any of its duly authorized committee or person thereof) [was authorized] to allot and issue the new Shares pursuant to the Share Subdivision, the [**REDACTED**] and [**REDACTED**];

(iii) the Board (or any of its duly authorized committee or person thereof) [was authorized] to agree to the [**REDACTED**] per [**REDACTED**] with the [**REDACTED**];

(iv) a general unconditional mandate [was granted] to our Directors to allot, issue and deal with Shares or securities convertible into Shares or options, warrants or similar rights to subscribe for Shares or such convertible securities and to make or grant offers, agreements or options (including but not limited to warrants, bonds, debentures, notes and other securities convertible into Shares) which would or might require the exercise of such powers, provided that the aggregate nominal value of Shares allotted or agreed conditionally or unconditionally to be allotted by our Directors other than pursuant to (A) a rights issue, (B) any scrip dividend scheme or similar arrangement providing for the allotment and issuance of Shares in lieu of the whole or part of a dividend on Shares in accordance with the Articles of Association, (C) the exercise of any subscription or conversion rights attaching to any warrants or securities which are convertible into Shares or in issue prior to the date of passing the relevant resolution or (D) a specific authority granted by the Shareholders in general meeting, shall not exceed the aggregate of (1) 20% of the total nominal value of the share capital of our Company in issue (excluding Treasury Shares) immediately following the completion of the Share Subdivision and the [**REDACTED**] (assuming the [**REDACTED**] is not exercised) and (2) the total nominal value of the share capital of our Company repurchased by our Company (if any) under the general mandate to repurchase Shares referred to in paragraph (e) below, such mandate to remain in effect during the period from the passing of the resolution until the earliest of the conclusion of our next annual general meeting, the end of the period within which we are required by any applicable law or the Articles of Association to hold our next annual general meeting or the date on which the resolution is varied or revoked by an ordinary resolution of the Shareholders in general meeting (the "**Applicable Period**");

(v) a general unconditional mandate [was granted] to our Directors to exercise all powers of our Company to repurchase on the Stock Exchange or on any other stock exchange on which the securities of our Company may be [**REDACTED**] and which is recognized by the SFC and the Stock Exchange for this purpose Shares with a total nominal value of not more than 10% of the total nominal value of the share capital of our Company in issue (excluding Treasury Shares, if any) immediately following completion of the Share Subdivision and the [**REDACTED**] (assuming the [**REDACTED**] is not exercised), such mandate to remain in effect during the Applicable Period (the "**Repurchase Mandate**"); and

(vi) the general unconditional mandate mentioned in paragraph (d) above be extended by the addition to the aggregate nominal value of the share capital of our Company which may be allotted, issued or dealt with or agreed conditionally or unconditionally to be allotted, issued or dealt with by our Directors pursuant to such general mandate of an amount representing the aggregate nominal value of the share capital of our Company repurchased by our Company pursuant to the mandate to repurchase Shares referred to in paragraph (e) above, provided that such extended amount shall not exceed 10% of the aggregate nominal value of our Company's share capital in issue (excluding Treasury Shares, if any) immediately following completion of the Share Subdivision and the [**REDACTED**] (assuming the [**REDACTED**] is not exercised).

5. Repurchase of Our Own Securities

The following paragraphs include, among others, certain information required by the Stock Exchange to be included in this document concerning the repurchase of our own securities.

(a) Provisions of the Listing Rules

The Listing Rules permit companies with a primary [**REDACTED**] on the Stock Exchange to repurchase their own Shares on the Stock Exchange subject to certain restrictions, the most important of which are summarized below:

(i) Shareholders' Approval

All proposed repurchase of Shares (which must be fully paid up) by a company with a primary [**REDACTED**] on the Stock Exchange must be approved in advance by an ordinary resolution of the shareholders, either by way of general mandate or by specific approval of a particular transaction.

Pursuant to a resolution passed by our then Shareholders on [●], the Repurchase Mandate was given to our Directors authorizing them to exercise all powers of our Company to repurchase Shares on the Stock Exchange, or on any other stock exchange on which the securities of our Company may be [**REDACTED**] and which is recognized by the SFC and the Stock Exchange for this purpose, with a total number up to 10% of the aggregate number of our Shares in issue immediately following the completion of the Share Subdivision and the [**REDACTED**] (excluding any Shares which may be issued pursuant to the exercise of the [**REDACTED**]) with such mandate to expire at the earliest of (i) the conclusion of the next annual general meeting of our Company (unless otherwise renewed by an ordinary resolution of our Shareholders in a general meeting, either unconditionally or subject to conditions), (ii) the expiration of the period within which our Company's next annual general meeting is required by the Articles of Association or any other applicable laws to be held, and (iii) the date on which it is varied or revoked by an ordinary resolution of our Shareholders in a general meeting.

(ii) Source of Funds

Any repurchases of Shares by us must be funded out of funds legally available for the purpose in accordance with our Memorandum and Articles of Association, the Listing Rules and the applicable laws of Hong Kong and the Cayman Islands. We are not permitted to [**REDACTED**] our Shares on the Stock Exchange for a consideration other than cash or for settlement otherwise than in accordance with the trading rules of the Stock Exchange from time to time. As a matter of Cayman Islands law, any purchases by our Company may be made out of profits or out of proceeds of a new issue of shares made for the purpose of the purchase or from sums standing to the credit of our share premium account or out of capital, if so authorized by the Articles of Association and subject to the Cayman Companies Act. Any premium payable on the purchase over the par value of the shares to be purchased must have been provided for out of profits or from sums standing to the credit of our share premium account or out of capital, if so authorized by the Articles of Association and subject to the Cayman Companies Act.

(iii) Trading Restrictions

The total number of shares which a listed company may repurchase on the Stock Exchange is the number of shares representing up to a maximum of 10% of the aggregate number of shares in issue (excluding Treasury Shares).

A company may not issue or announce a proposed issue of new securities for a period of 30 days immediately following a repurchase (other than an issue of securities pursuant to an exercise of warrants, share options or similar instruments requiring our Company to issue securities which were outstanding prior to such repurchase) without the prior approval of the Stock Exchange. In addition, a listed company is prohibited from repurchasing its shares on the Stock Exchange if the purchase price is 5% or more than the average closing market price for the five preceding trading days on which its shares were traded on the Stock Exchange. The Listing Rules also prohibit a listed company from repurchasing its securities if the repurchase would result in the number of listed securities which are in the hands of the public falling below the relevant prescribed minimum percentage as required by the Stock Exchange. A listed company is required to procure that the broker appointed by it to effect a repurchase of securities discloses to the Stock Exchange such information with respect to the repurchase as the Stock Exchange may require.

(iv) Status of Repurchased Shares

Pursuant to the Listing Rules, the shares repurchased by an issuer shall be held as Treasury Shares or cancelled. The [**REDACTED**] of all shares which are held as Treasury Shares shall be retained. The issuer shall ensure that Treasury Shares are appropriately identified and segregated. The [**REDACTED**] of all repurchased securities (whether on the Stock Exchange or otherwise) but not held as Treasury Shares is automatically cancelled upon repurchase and our Company must apply for [**REDACTED**] of any further Shares in the normal way. The relative certificates must be cancelled and destroyed as soon as reasonably practicable following settlement of any such repurchase. However, the purchase of shares will not be taken as reducing the amount of the authorized share capital of our Company under the Cayman Companies Act.

(v) Suspension of Repurchase

A listed company may not make any repurchase of securities after a price sensitive development has occurred or has been the subject of a decision until such time as the price sensitive information has been made publicly available. In particular, during the period of one month immediately preceding the earlier of (a) the date of the board meeting (as such date is first notified to the Stock Exchange in accordance with the Listing Rules) for the approval of a listed company's results for any year, half-year, quarterly or any other interim period (whether or not required under the Listing Rules) and (b) the deadline for publication of an announcement of a listed company's results for any year or half-year under the Listing Rules, or quarterly or any other interim period (whether or not required under the Listing Rules) and ending on the date of results announcement, the listed company may not repurchase its shares on the Stock Exchange other than in exceptional circumstances. In addition, the Stock Exchange may prohibit a repurchase of securities on the Stock Exchange if the Stock Exchange considers the listed company has breached the Listing Rules.

(vi) Reporting Requirements

Certain information relating to repurchases of securities on the Stock Exchange or otherwise must be reported to the Stock Exchange not later than 30 minutes before the earlier of the commencement of the morning trading session or any pre-opening session on the following Business Day. In addition, a [**REDACTED**] company's annual report is required to disclose details regarding repurchases of securities made during the year, including a monthly analysis of the number of securities repurchased, the purchase price per share or the highest and lowest price paid for all such repurchases, where relevant, and the aggregate prices paid.

(vii) Core Connected Persons

The Listing Rules prohibit a company from knowingly purchasing securities on the Stock Exchange from a "core connected person", that is, a director, chief executive or substantial shareholder of our Company or any of its subsidiaries or a close associate of any of them (as defined in the Listing Rules) and a core connected person shall not knowingly sell his securities to our Company.

(b) Reasons for Repurchase

Our Directors believe that it is in the best interest of our Company and Shareholders for our Directors to have general authority from the Shareholders to enable our Company to repurchase Shares in the market. Such repurchases may, depending on market conditions and funding arrangements at the time, lead to an enhancement of the net asset value per Share and/or earnings per Share and will only be made where our Directors believe that such repurchases will benefit our Company and Shareholders.

(c) Funding of Repurchases

Repurchase of the Shares must be funded out of funds legally available for such purpose in accordance with the Articles of Association and the applicable laws of the Cayman Islands.

Our Directors may not repurchase the Shares on the Stock Exchange for a consideration other than cash or for settlement otherwise than in accordance with the trading rules of the Stock Exchange. Subject to the foregoing, our Directors may make repurchases out of profits of the Company, out of the share premium account of the Company or out of the proceeds of a new issuance of shares made for the purpose of the repurchase and, in the case of any premium payable on the repurchase, out of profits of our Company or from sums standing to the credit of the share premium account of our Company. Subject to the Cayman Companies Act and if so authorized by the Articles of Association, a repurchase may also be made out of capital.

However, our Directors do not propose to exercise the general mandate to such an extent as would, in the circumstances, have a material adverse effect on the working capital requirements of our Company or its gearing levels which, in the opinion of our Directors, are from time to time appropriate for our Company.

(d) General

The exercise in full of the Repurchase Mandate, on the basis of [**REDACTED**] Shares in issue (excluding Treasury Shares) immediately following completion of the Share Subdivision and the [**REDACTED**] (assuming the [**REDACTED**] is not exercised), could accordingly result in up to [**REDACTED**] Shares being repurchased by our Company during the period prior to: (i) the conclusion of the next annual general meeting of our Company; (ii) the expiry of the period within which our Company is required by the Articles of Association or any applicable law to hold our annual general meeting; or (iii) the variation or revocation by an ordinary resolution of the Shareholders passed in a general meeting, whichever is the earliest.

None of our Directors nor, to the best of their knowledge having made all reasonable enquiries, any of their close associates (as defined in the Listing Rules) currently intends to sell any Shares to us or our subsidiaries.

Our Directors [have undertaken] to the Stock Exchange that, so far as the same may be applicable, they will exercise the repurchase mandate in accordance with the Listing Rules, the Articles of Association, the Cayman Companies Act or any other applicable laws of the Cayman Islands.

Subject to the applicable requirements under the Listing Rules, our Company may cancel the repurchased Shares following settlement of any such repurchase or hold them as Treasury Shares, subject to, for example, market conditions and its capital management needs at the relevant time of the repurchases.

Should our Company decide to hold repurchased Shares as Treasury Shares, we will, upon completion of the Share repurchase, withdraw the repurchased Shares from [**REDACTED**] and register the Treasury Shares in our Company's name. We may re-deposit its Treasury Shares into [**REDACTED**] only if it has an imminent plan to resell these Treasury Shares on the Stock Exchange and will complete such resale as soon as possible. We will have appropriate measures to ensure that it would not exercise any shareholders' rights or receive any entitlements which would otherwise be suspended under the relevant laws with respect to Treasury Shares. These measures include, for example, an approval by the Board that (i) our Company should procure its [**REDACTED**] not to give any instructions to [**REDACTED**] to vote at general meetings for the Treasury Shares deposited with [**REDACTED**]; and (ii) in the case of dividends or distributions, our Company should withdraw the Treasury Shares from [**REDACTED**], and either re-register them in our Company's name as Treasury Shares or cancel them, in each case before the record date for the dividends or distributions.

Holders of Treasury Shares (if any) shall abstain from voting on matters that require Shareholders' approval at our Company's general meetings.

If, as a result of a repurchase of our Shares pursuant to the repurchase mandate, a Shareholder's proportionate interest in our voting rights is increased, such increase will be treated as an acquisition for the purpose of the Takeovers Code. Accordingly, a Shareholder or a group of Shareholders acting in concert could obtain or consolidate control of us and become obliged to make a mandatory offer in accordance with Rule 26 of the Takeovers Code. Save as aforesaid, our Directors are not aware of any consequences which would arise under the Takeovers Code as a consequence of any repurchases pursuant to the repurchase mandate.

Any repurchase of Shares which results in the number of Shares held by the public being reduced to less than 25% of our Shares than in issue could only implemented with the approval of the Stock Exchange to waive the Listing Rules requirements regarding the public shareholding referred to above. It is believed that a waiver of this provision would not normally be given other than in exceptional circumstances.

No core connected person, as defined in the Listing Rules, has notified us that he/she/it has a present intention to sell their Shares to us, or has undertaken not to do so, if the repurchase mandate is exercised.

B. CORPORATE REORGANIZATION

In preparation of the [**REDACTED**] and in order to streamline our corporate structure, we underwent and conducted the Reorganization before the [**REDACTED**]. For details, see "History, Reorganization and Corporate Development — Reorganization."

C. FURTHER INFORMATION ABOUT OUR BUSINESS

1. Summary of Material Contract

We have entered into the following contract (not being contracts entered into in the ordinary course of business) within the two years immediately preceding the date of this document that is or may be material:

(i) the [**REDACTED**].

2. Intellectual Property Rights

(a) Trademarks

As of the Latest Practicable Date, we had registered the following trademarks which we consider to be or may be material to our business:

No.	Trademark	Owner	Class	Place of registration	Expiry date	Registration number
1 . . .	美佳印	Shandong Huge	5	PRC	July 6, 2031	8414896
2 . . .	美益汀	Shandong Huge	3	PRC	May 13, 2036	16333139
3 . . .	美益汀	Shandong Huge	5	PRC	May 13, 2036	16333126
4 . . .	美益汀	Shandong Huge	35	PRC	March 27, 2036	16333269

No.	Trademark	Owner	Class	Place of registration	Expiry date	Registration number
5 . . .	美益汀	Shandong Huge	10	PRC	March 27, 2036	16333323
6 . . .	美佳印	Shandong Huge	9,10	PRC	July 27, 2031	51301025
7 . . .	沪鸽·美悦 HUGE·MEIYUE	Shandong Huge	3,10,21	PRC	August 27, 2031	52966865
8 . . .	HUGE 沪鸽	Shandong Huge	3	PRC	December 6, 2036	17722337
9 . . .	HUGE 沪鸽	Shandong Huge	5,10	PRC	October 6, 2036	17722468
10 . .	HUGE 沪鸽	Shandong Huge	10	PRC	October 20, 2036	17843211
11 . .	凯晶	Shandong Huge	10	PRC	January 6, 2037	18484062
12 . .	凯丽	Shandong Huge	10	PRC	January 6, 2037	18484063
13 . .	凯丰	Shandong Huge	10	PRC	January 6, 2037	18484064
14 . .	凯标	Shandong Huge	10	PRC	January 6, 2037	18484065
15 . .	凯标 KAIBIAO	Shandong Huge	10	PRC	August 6, 2027	4416723
16 . .	凯丽 KAILI	Shandong Huge	10	PRC	May 27, 2027	4345423
17 . .	凯彤 KAITONG	Shandong Huge	10	PRC	May 27, 2027	4345421
18 . .	凯晶 KAIJING	Shandong Huge	10	PRC	May 27, 2027	4345422
19 . .	凯丰 KAIFENG	Shandong Huge	10	PRC	May 27, 2027	4345424
20 . .	HT DENTAL	Shandong Huge	3,5,10,35,44	PRC	June 20, 2028	24699056
21 . .	HUGE DENTAL	Shandong Huge	3,5,10,35,44	PRC	June 27, 2029	24701992
22 . .	沪鸽口腔	Shandong Huge	3,5,10,35,44	PRC	August 27, 2028	24713017
23 . .	HUGE 沪鸽	Shandong Huge	21	PRC	February 27, 2029	30196464
24 . .	沪鸽美悦	Shandong Huge	10	PRC	February 13, 2029	30591298
25 . .	沪鸽	Shandong Huge	21	PRC	March 20, 2030	38505556
26 . .	沪鸽课堂	Shandong Huge	41	PRC	October 6, 2030	43866429

No.	Trademark	Owner	Class	Place of registration	Expiry date	Registration number
27 . .	HUGE 沪鸽	Shandong Huge	5, 10	Hong Kong	December 1, 2034	306742639
28 . .	HUGE	Shandong Huge	5, 8, 21	PRC	January 20, 2035	77611609
29 . .	HUGE 沪鸽口腔	Shandong Huge	5, 8, 21	PRC	January 27, 2035	77607485

(b) Patents

Registered Patents

As of the Latest Practicable Date, we owned the following registered patents which we consider to be or may be material to our business:

No.	Patent	Type of patent	Place of registration	Patent number	Owner	Expiration date
1 . .	Four-layer color composite resin block and preparation method	Invention	PRC	ZL201310233678.X	Shandong Huge	June 12, 2033
2 . .	Laser processing device for removable dentures and processing method	Invention	PRC	ZL201510271309.9	Shandong Huge	May 24, 2035
3 . .	Monitoring device for implanted products and monitoring method	Invention	PRC	ZL201510455549.4	Shandong Huge	July 28, 2035
4 . .	Stain-resistant hard resin denture and preparation method	Invention	PRC	ZL202110276248.0	Shandong Huge	March 14, 2041
5 . .	Orthodontic dental surface etching device	Invention	PRC	ZL202111564437.4	Shandong Huge	December 19, 2041
6 . .	Resin block for complete dentures and digital fabrication method for complete dentures	Invention	PRC	ZL202210315719.9	Shandong Huge	March 28, 2042

No.	Patent	Type of patent	Place of registration	Patent number	Owner	Expiration date
7 . .	Automatic double-sided tape application mechanism for curved surfaces	Invention	PRC	ZL201911009290.5	Shandong Huge	October 22, 2039
8 . .	Composite resin for 3D-printed high-transparency, non-yellowing, antibacterial surgical guides for implants, and preparation method and application	Invention	PRC	ZL202311836251.9	Shandong Huge	December 27, 2043
9 . .	Soft elastic resin pelletizing machine	Invention	PRC	ZL202111178041.6	Shandong Huge	October 8, 2041
10 . .	Curved surface stitching method with controllable precision based on surface intersection	Invention	PRC	ZL201511023288.5	Qingdao Technology	December 29, 2035
11 . .	Model-based virtual tooth generation method for clear aligners	Invention	PRC	ZL201511020076.1	Qingdao Technology	December 29, 2035
12 . .	Model-based virtual gingiva generation method for clear aligners	Invention	PRC	ZL201511024104.7	Qingdao Technology	December 29, 2035
13 . .	Automatic tooth mesh model segmentation method based on principal curvature	Invention	PRC	ZL201511023297.4	Qingdao Technology	December 29, 2035
14 . .	Dental arch curve generation method	Invention	PRC	ZL201610576356.9	Qingdao Technology	July 20, 2036
15 . .	Automated cleaning and disinfection system for clear aligner production lines and disinfection method	Invention	PRC	ZL201610907930.4	Qingdao Technology	October 18, 2036

No.	Patent	Type of patent	Place of registration	Patent number	Owner	Expiration date
16. .	Rapid cleaning and recycling device for 3D-printed resin materials	Invention	PRC	ZL201611235134.7	Qingdao Technology	December 27, 2036
17. .	Gingiva generation method for bracket-free orthodontics	Invention	PRC	ZL201610906364.5	Qingdao Technology	October 18, 2036
18. .	Robotic arm spatial trajectory precision positioning method for cutting bracket-free clear aligners	Invention	PRC	ZL201710167919.3	Qingdao Technology	March 20, 2037
19. .	Partial surface subdivision method	Invention	PRC	ZL201610912196.0	Qingdao Technology	October 18, 2036
20. .	Interactive segmentation method for full-arch triangular mesh dental models	Invention	PRC	ZL201610907688.0	Qingdao Technology	October 18, 2036
21. .	Tooth segmentation method based on peak clustering	Invention	PRC	ZL201910641265.2	Qingdao Technology	July 15, 2039
22. .	Intelligent personalized clear aligner model cutting flexible production line and control method	Invention	PRC	ZL201711119030.4	Qingdao Technology	November 13, 2037
23. .	Automated multi-hole object gripping device	Invention	PRC	ZL201710167948.X	Qingdao Technology	March 20, 2037
24. .	Custom aligner fabrication method	Invention	PRC	ZL201811299030.1	Qingdao Technology	November 1, 2038
25. .	Single-component light-curable composite material with fluoride ion release for dental restorations and application	Invention	PRC	ZL201611236105.2	Rizhao Huge	December 27, 2036

No.	Patent	Type of patent	Place of registration	Patent number	Owner	Expiration date
26. .	Preparation method for nanostructured filler powder for dental composite resin filler	Invention	PRC	ZL201710385781.4	Rizhao Huge	May 25, 2037
27. .	Self-adhesive resin cement with self-curing stability and preparation method	Invention	PRC	ZL202311480058.6	Rizhao Huge	November 7, 2043
28. .	Photochromic dental composite material and preparation method	Invention	PRC	ZL202210523946.0	Rizhao Huge	May 13, 2042
29. .	A low-oxygen inhibition dental adhesive	Invention	PRC	ZL202410062644.7	Shandong Huge	January 15, 2044
30. .	A mineralized collagen gel loaded with gingival mesenchymal stem cell exosomes and its preparation method	Invention	PRC	ZL202210351949.0	Shandong Huge	September 25, 2043
31. .	A dental implant with a surface coating that promotes bone growth and has antibacterial properties and its preparation method	Invention	PRC	ZL202510853393.9	Shandong Huge	December 15, 2045

Patents under Application

As of the Latest Practicable Date, we have applied for the registration of the following patents which we consider to be or may be material to our business:

No.	Patent	Type of patent	Place of registration	Application number	Applicant	Application date
1 . .	A flexible resin disc for dental CAM applications and its preparation method	Invention	PRC	202110727941.5	Shandong Huge	June 29, 2021

No.	Patent	Type of patent	Place of registration	Application number	Applicant	Application date
2 . .	A removable denture and its additive or subtractive manufacturing method	Invention	PRC	202310434281.0	Shandong Huge	April 21, 2023
3 . .	A high-stability and high-fluoride-release anti-caries agent and its preparation method	Invention	PRC	202311059500.8	Shandong Huge	August 22, 2023

(c) Software Copyrights

As of the Latest Practicable Date, we were the registered proprietor of the following software copyrights which we consider to be or may be material to our business:

No.	Subject	Owner	Certification number	First published date	Certification date
1 . .	Resin Tooth Morphology Design Software V1.0 (樹脂牙形態設計軟件V1.0)	Shandong Huge	2014SR042683	January 1, 2014	April 14, 2014
2 . .	Huge Inspection System Software V1.0 (滬鴿檢驗系統軟件V1.0)	Shandong Huge	2014SR042689	January 1, 2014	April 14, 2014
3 . .	Resin Tooth Mold Processing Software V1.0 (樹脂牙模具加工軟件V1.0)	Shandong Huge	2014SR042685	January 1, 2014	April 14, 2014
4 . .	Zirconia Carving Software V1.0 (氧化鋯雕刻軟件V1.0)	Shandong Huge	2014SR042693	January 1, 2014	April 14, 2014

(d) Domain Names

As of the Latest Practicable Date, we had registered the following internet domain names which we consider to be or may be material to our business:

No.	Domain name	Owner	Expiry date
1. . . .	hugedental.com	Shandong Huge	June 28, 2026
2. . . .	vincismile.com	Shandong Huge	June 21, 2026
3. . . .	hugedent.cn	Shanghai Huge Medical Devices	August 16, 2032
4. . . .	hugedent.com	Shandong Huge	April 18, 2026
5. . . .	vincismile.cn	Shandong Huge	August 7, 2026

Save as aforesaid, as of the Latest Practicable Date, there were no other trade or service marks, patents or other intellectual or industrial property rights which were material in relation to our Group's business.

D. FURTHER INFORMATION ABOUT OUR DIRECTORS, CHIEF EXECUTIVE AND SUBSTANTIAL SHAREHOLDERS

1. Disclosure of Interests

(a) Interests and Short Positions of the Directors and Chief Executive of Our Company in the Shares, Underlying Shares and Debentures of Our Company and Our Associated Corporation

Save as disclosed in the section headed "Substantial Shareholders," as of the date of this document and immediately following the completion of the Share Subdivision and the [**REDACTED**] (assuming the [**REDACTED**] is not exercised) the interests of our Directors and chief executive in our Shares, underlying Shares or debentures of our Company or any of our associated corporations (within the meaning of Part XV of the SFO) which will have to be notified to us and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions in which they are taken or deemed to have under such provisions of the SFO), or which will be required, pursuant to section 352 of the SFO, to be entered in the register referred to therein, or which will be required to be notified to us and the Stock Exchange pursuant to the Model Code for Securities Transactions by Directors of Listed Issuers contained in the Listing Rules, are set out as follows:

(i) Long positions in our Company

		As of the date of this document		Immediately after the Share Subdivision and the [REDACTED]	
Name	**Nature of interest**	**Number of Shares(1)**	**Approximate percentage of interest in our Company**	**Number of Shares(1)**	**Approximate percentage of interest in our Company**
Mr. LIU Qin	Interests in controlled corporation(2)	1,467,962	3.65%	[5,871,848]	[**REDACTED**]%
Ms. ZHANG Yongjing	Interests in controlled corporation(3)	170,000	0.42%	[680,000]	[**REDACTED**]%
Mr. XIANG Longsheng	Interests in controlled corporation(4)	40,000	0.10%	[160,000]	[**REDACTED**]%

Notes:

(1) All interests stated are long positions.

(2) Mr. LIU Qin is deemed to be interested in the Shares held by his wholly-owned entity, Huge Bao Innovative Ltd., by virtue of the SFO.

(3) Ms. ZHANG Yongjing is deemed to be interested in the Shares held by her wholly-owned entity, HDMC Voyager YJZ Ltd., by virtue of the SFO.

(4) Mr. XIANG Longsheng is deemed to be interested in the Shares held by his wholly-owned entity, HDMC Voyager LSX Ltd., by virtue of the SFO.

(b) Interests of the Substantial Shareholders in the Shares and Underlying Shares of Our Company and of Other Members of Our Group

(i) Interests in our Company

Save as disclosed below and in the section headed "Substantial Shareholders," immediately following the completion of the Share Subdivision and the [**REDACTED**] (assuming the [**REDACTED**] is not exercised), our Directors are not aware of any other person (not being a Director or chief executive of our Company) who will have an interest or short position in the Shares or underlying Shares which would fall to be disclosed to us and the Stock Exchange under the provisions of Divisions 2 and 3 of Part XV of the SFO, or who is, directly or indirectly, interested in 10% or more of the nominal value of any class of share capital carrying rights to vote in all circumstances at the general meetings of the Company.

(ii) Interests in other members of our Group

Name of subsidiary	Name of shareholder	Nature of interest	Approximate percentage of shareholding interest
Rizhao Huge	Mr. JIA Weitao (賈為濤)(1)	Beneficial owner	25.00%
Qingdao Technology . .	Ningbo Meishan Bonded Port Area Chuangsheng Investment Management Partnership (Limited Partnership) (寧波梅山保稅港區創升投資管理合夥企業(有限合夥))(2)	Beneficial owner	24.68%

Notes:

(1) As of the Latest Practicable Date, Mr. JIA Weitao is the director of Rizhao Huge.

(2) As of the Latest Practicable Date, Ningbo Meishan Bonded Port Area Chuangsheng Investment Management Partnership (Limited Partnership) is controlled by its general partner, Mr. WANG Kai (王凱).

2. Directors' Service Contracts and Letters of Appointment

(a) Executive Directors

Each of the executive Directors [has] entered into a service contract with our Company under which they agreed to act as an executive Directors for an initial term of three years commencing from the date of his appointment as a Director and continue for a period of three years or until the third annual general meeting of the Company since the [**REDACTED**], whichever is earlier, which may be terminated by not less than three months' notice in writing served by either the executive Director or our Company. The appointments of the executive Directors are subject to the provisions of retirement and rotation of Directors under the Articles of Association.

(b) Independent non-executive Directors

Each of the independent non-executive Directors [has] signed an appointment letter with our Company for a term of three years with effect from the date of his appointment as a Director and continue for a period of three years or until the third annual general meeting of the Company since the [**REDACTED**], whichever is earlier. The appointments of the independent non-executive Directors are subject to the provisions of retirement and rotation of Directors under the Articles of Association.

3. Director's Remuneration

Save as disclosed in "Directors and Senior Management" of this document and Note 8 to the Accountant's Report as set out in Appendix I to this document, for the financial years ended December 31, 2023, 2024 and 2025, none of our Directors received other remunerations of benefits in kind from us.

There was no arrangements under which any Director has waived or agrees to waive any emolument during the Track Record Period.

4. Disclaimers

Save as disclosed in this section:

(i) there is no existing or proposed service contract (excluding any contract expiring or determinable by the employer within one year without payment of compensation (other than statutory compensation)) between our Directors and any member of our Group;

(ii) none of our Directors or the experts named in "— E. Other Information — 8. Qualifications and Consents of Experts" has any direct or indirect interest in the promotion of, or in any assets which have been, within the two years immediately preceding the date of this document, acquired or disposed of by or leased to any member of our Group, or are proposed to be acquired or disposed of by or leased to any member of our Group;

(iii) save in connection with the [**REDACTED**], none of our Directors nor any of the experts named in "— E. Other Information — 8. Qualifications and Consents of Experts" is materially interested in any contract or arrangement subsisting at the date of this document which is significant in relation to the business of our Group as a whole; and

(iv) none of our Directors or their respective close associates or any Shareholders of our Company (who to the knowledge of our Directors owns more than 5% of the number of our issued shares) has any interest in our five largest suppliers or our five largest customers during the Track Record Period.

E. OTHER INFORMATION

1. Estate Duty

Our Directors have been advised that no material liability for estate duty is likely to impose on our Company or any of the subsidiaries of our Company.

2. Litigation

As of the Latest Practicable Date, we were not aware of any litigation or arbitration proceedings of material importance pending or threatened against us or any of our Directors that would have a material adverse effect on our financial condition or results of operations.

3. Joint Sponsors

The Joint Sponsors satisfy the independence criteria applicable to sponsors set out in Rule 3A.07 of the Listing Rules. The fees paid and payable to the Joint Sponsors are US$800,000 in aggregate.

The Joint Sponsors have made an application on our Company's behalf to the Listing Committee of the Stock Exchange for the granting of the approval for the [**REDACTED**] of, and permission to [**REDACTED**], all the Shares in issue and to be issued as mentioned in this document. All necessary arrangements [have been made] for the Shares to be admitted into [**REDACTED**].

4. Preliminary Expenses

Our Company did not incur any material preliminary expenses.

5. No Material Adverse Change

Our Directors confirm that there has been no material adverse change in the financial or trading position or prospects of our Group since December 31, 2025 (being the date to which the latest consolidated financial statements of our Group were prepared).

6. Promoter

Our Company has no promoter for the purpose of the [**REDACTED**]. Within the two years immediately preceding the date of this document, no cash, securities or other benefit has been paid, allotted or given nor are any proposed to be paid, allotted or given to any promoters in connection with the [**REDACTED**] and the related transactions described in this document.

7. Agency Fees or Commissions Paid or Payable

Save as disclosed in the section headed "[**REDACTED**]" in this document, within the two years immediately preceding the date of this document, no commissions, discounts, brokerages or other special terms have been granted in connection with the issue or sale of any share or loan capital of our Company or any of our subsidiaries. Within the two years preceding the date of this document, no commission has been paid or is payable for subscribing or agreeing to subscribe, or procuring or agreeing to procure the subscriptions, for any Shares in our Company.

8. Qualifications and Consents of Experts

The following are the qualifications of the experts who have given opinions or advice which are contained in this document:

Name	Qualification
China International Capital Corporation Hong Kong Securities Limited	Licensed to conduct Type 1 (dealing in securities), Type 2 (dealing in futures contracts), Type 4 (advising on securities), Type 5 (advising on futures contracts) and Type 6 (advising on corporate finance) of regulated activities as defined under the SFO.
DBS Asia Capital Limited	Licensed to conduct Type 1 (dealing in securities), Type 4 (advising on securities) and Type 6 (advising on corporate finance) regulated activities under the SFO.
Ernst & Young	Certified Public Accountants and Registered Public Interest Entity Auditor
Commerce & Finance Law Offices	Legal advisors to our Company as to PRC law
Maples and Calder (Hong Kong) LLP	Legal advisors to our Company as to Cayman Islands law
Ashurst Horitsu Jimusho Gaikokuho Kyodo Jigyo	Legal advisors to our Company as to International Sanctions Laws
Frost & Sullivan (Beijing) Inc., Shanghai Branch Co.	Industry consultant
APAC Asset Valuation and Consulting Limited	Independent property valuer

Each of the experts named above has given and has not withdrawn its consent to the issue of this document with the inclusion of its report, letter, summary of valuations, valuation certificates and/or legal opinion (as the case may be) and references to its name included in the form and context in which it respectively appears.

Save as disclosed the "[**REDACTED**]" section, none of the experts named above is interested legally or beneficially in any shares of any member of our Group or has any right (whether legally enforceable or not) to subscribe for or to nominate persons to subscribe for securities in any member of our Group.

9. Binding Effect

This document shall have the effect, if any application is made pursuant hereto, of rendering all persons concerned bound by all the provisions (other than the penal provisions) of sections 44A and 44B of the Companies (Winding Up and Miscellaneous Provisions) Ordinance so far as applicable.

10. Bilingual Document

The English language and Chinese language versions of this document are being published separately, in reliance upon the exemption provided by section 4 of the Companies (Exemption of Companies and Prospectuses from Compliance with Provisions) Notice (Chapter 32L of the Laws of Hong Kong). In case of any discrepancies between the English language version and Chinese language version of this document, the English language version shall prevail.

11. Miscellaneous

(a) Save as disclosed in "History, Reorganization and Corporate Structure" and in connection with the [**REDACTED**]: (i) within the two years preceding the date of this document, no share or loan capital of our Company or any of our subsidiaries has been issued nor agreed to be issued fully or partly paid either for cash or for a consideration other than cash; and (ii) no share or loan capital of our Company is under option or is agreed conditionally or unconditionally to be put under option.

(b) We have not issued nor agreed to issue any founder shares, management shares or deferred shares.

(c) There are no arrangements under which future dividends are waived or agreed to be waived.

(d) There have been no interruptions in our business which may have or have had a significant effect on our financial position in the last 12 months immediately preceding the date this document.

(e) There are no restrictions affecting the remittance of profits or repatriation of capital by us into Hong Kong from outside Hong Kong.

(f) No part of the equity or debt securities of our Company, if any, is currently listed on or dealt in on any stock exchange or trading system, and no such listing or permission to list on any stock exchange other than the Stock Exchange is currently being or agreed to be sought.

(g) Our Company has no outstanding convertible debt securities or debentures.